Den-Mei Brain Tumor Education Foundation, Taichung, Taiwan Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2005
NCT02772094
First Marketed Drug
1998
doxycycline (vibramycin)
First NDA Approval
None
Last Known Activity
2005

Timeline

NOW
  • Now

Alternative names

DEN-MAT

Active Ingredients

Marketed Drugs (1)

doxycycline (vibramycin) (1998)

Drugs in Phase 2 Trials (1)

tumor-pulsed dendritic cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 2)

Glioma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1